The U.S. Food and Drug Administration (FDA) approved Tauklarify (florquinitau F 18) for use in positron emission tomography (PET) scans. Lantheus Holdings developed this radioactive diagnostic agent to detect tau neurofibrillary tangles in adults with cognitive impairment.
Tau protein accumulation serves as a primary pathological hallmark of Alzheimer's disease and correlates closely with cognitive decline. Tauklarify enters the market to compete with Eli Lilly’s Tauvid, which the FDA approved in 2020.
These imaging agents allow clinicians to diagnose Alzheimer's accurately and monitor the effectiveness of new targeted therapies. Lantheus plans to support ongoing therapeutic programs while evaluating a broader commercial launch strategy.